The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis

Andrew Blauvelt(Veterans Health Administration), Andrea Chiricozzi(Università Cattolica del Sacro Cuore)

Clinical Reviews in Allergy & Immunology

August 14, 2018

10.1007/s12016-018-8702-3

Cited by 738

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

|New England Journal of Medicine|2016|2k

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

|British Journal of Dermatology|2020|590

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

|The Lancet|2015|566

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

|The Lancet|2021|538

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

|JAMA Dermatology|2019|505